Calls of the Day: Crowdstrike, Cheniere Energy, 3M, Abbott Labs, Abbvie and Eli Lilly
The Investment Committee debate the latest Calls Of The Day. How many of the best sci-fi movies ever made have you watched?
Top Stock Reports for AbbVie, ADP & Analog Devices
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Automatic Data ...
Jim Cramer Says AbbVie Inc. (ABBV) ‘Is Doing Very, Very Well’
We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch. In this article, we are ...
FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year
Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for motor ...
FiercePharma12h
3rd time's the charm: AbbVie scores FDA nod for continuous Parkinson's disease therapy Vyalev
AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system ...
Crain's Chicago Business8h
New AbbVie Parkinson’s drug finally gets green light to hit U.S. market
After two previous failed attempts with the FDA, AbbVie now has one more offering in its lineup — a critical step as it ...
Fintel on MSN14h
Bernstein Initiates Coverage of AbbVie (ABBV) with Market Perform Recommendation
Fintel reports that on October 17, 2024, Bernstein initiated coverage of AbbVie (NYSE:ABBV) with a Market Perform ...
AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease
Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.
24/7 Wall St2d
Dividend Aristocrat AbbVie Just Paid Investors; Here's How Much They Received
AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.55, payable on Tuesday Oct.
AbbVie Gets FDA OK for Vyalev in Adults With Advanced Parkinson's Disease
AbbVie has finally won Food and Drug Administration approval of its Vyalev therapy for patients with advanced Parkinson's disease. AbbVie on Thursday said the FDA green light makes Vyalev the first ...
Crain's Chicago Business3d
AbbVie tries to fast-track new cancer drug for approval to join 2 others in its pipeline
There are no approved therapies to tackle c-Met protein overexpression, AbbVie said in a press release. C-Met is a receptor ...
FDA Approves AbbVie's Parkinson's Disease Drug Vyalev
(RTTNews) - AbbVie Inc. (ABBV) Thursday said that the U.S. Food and Drug Administration (FDA) has approved Vyalev for the treatment of motor fluctuations in adults with advanced Parkinson's disease ...